SCHEMBL3340085

SCHEMBL3340085

COc1ccc(Cl)c(Oc2cc(-c3cc(F)cc(F)c3)ncc2C(=O)O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.40
SLC22A12 Q96S37 1/20 0.40
SCN9A Q15858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 3/20 0.39
EIF4E P06730 3/20 0.37
PLG P00747 1/20 0.37
PLAU P00749 1/20 0.37
POLB P06746 2/20 0.37
DHODH Q02127 1/20 0.37
LDHA P00338 2/20 0.36
CTSA P10619 1/20 0.36
PRKAB2 O43741 1/20 0.36
PRKAG1 P54619 1/20 0.36
PRKAA2 P54646 1/20 0.36
PRKAA1 Q13131 1/20 0.36
PRKAG3 Q9UGI9 1/20 0.36
PRKAG2 Q9UGJ0 1/20 0.36
PRKAB1 Q9Y478 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3339524 0.88 KMO (0.44) KMOSCN9ASMN1; SMN2KDM4EEIF4E
SCHEMBL3343610 0.87 CYP1A2 (0.43) SMN1; SMN2KDM4EPOLBLMNA
SCHEMBL3342009 0.83 LDHA (0.42) LDHA
SCHEMBL3347867 0.82 NPC1 (0.42) KMOSLC22A12SCN9ASMN1; SMN2KDM4E
SCHEMBL3345443 0.80 KMO (0.44) KMOSCN9ASMN1; SMN2KDM4EEIF4E
SCHEMBL3345623 0.79 SCN9A (0.41) KMOSLC22A12SCN9AKDM4EPOLB
SCHEMBL3341691 0.76 KMO (0.46) KMOSCN9ASMN1; SMN2KDM4EEIF4E
SCHEMBL3341188 0.75 LDHA (0.46) SCN9ADHODHLDHA
SCHEMBL3347331 0.75 KMO (0.46) KMODHODHLDHA
SCHEMBL3342486 0.73 DHODH (0.42) KMOSCN9ASMN1; SMN2KDM4EEIF4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160386-A1 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT 2010-06-24 US disclosed
US-20100160386-A1 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT 2010-06-24 US disclosed
US-20100160386-A1 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160386-A1 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS PPARA, PPARD, PPARG KMO 1885/4885SLC22A12 2108/4885SCN9A 2847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.